CL2008003067A1 - Compuesto 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida, modulador de receptores nicotinicos alfa-7; proceso de preparacion; composicion farmaceutica y su proceso de preparacion; y su uso en el tratamiento de trastornos psicoticos, intelectuales, inflamatorios. - Google Patents
Compuesto 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida, modulador de receptores nicotinicos alfa-7; proceso de preparacion; composicion farmaceutica y su proceso de preparacion; y su uso en el tratamiento de trastornos psicoticos, intelectuales, inflamatorios.Info
- Publication number
- CL2008003067A1 CL2008003067A1 CL2008003067A CL2008003067A CL2008003067A1 CL 2008003067 A1 CL2008003067 A1 CL 2008003067A1 CL 2008003067 A CL2008003067 A CL 2008003067A CL 2008003067 A CL2008003067 A CL 2008003067A CL 2008003067 A1 CL2008003067 A1 CL 2008003067A1
- Authority
- CL
- Chile
- Prior art keywords
- preparation process
- dioxol
- psychotic
- ylamino
- difluoro
- Prior art date
Links
- OFJQZNTUOPOEQR-UHFFFAOYSA-N 2-[3-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]-5-(2,6-dimethylpyridin-4-yl)-1,2,4-triazol-1-yl]-n-ethylacetamide Chemical compound CCNC(=O)CN1N=C(NC=2C=C3OC(F)(F)OC3=CC=2)N=C1C1=CC(C)=NC(C)=C1 OFJQZNTUOPOEQR-UHFFFAOYSA-N 0.000 title abstract 2
- 208000028017 Psychotic disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 title 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 229940075993 receptor modulator Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Compuesto 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida, proceso para prepararlo, composición farmacéutica, proceso para prepararla y su uso en el tratamiento o profilaxis de trastornos psicóticos, inflamatorios y mediados por receptores nicotínicos alfa 7.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07118822 | 2007-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008003067A1 true CL2008003067A1 (es) | 2009-11-27 |
Family
ID=39047591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008003067A CL2008003067A1 (es) | 2007-10-18 | 2008-10-16 | Compuesto 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida, modulador de receptores nicotinicos alfa-7; proceso de preparacion; composicion farmaceutica y su proceso de preparacion; y su uso en el tratamiento de trastornos psicoticos, intelectuales, inflamatorios. |
Country Status (18)
Country | Link |
---|---|
US (1) | US8404851B2 (es) |
EP (1) | EP2205594B1 (es) |
JP (1) | JP2011500624A (es) |
CN (1) | CN101827839B (es) |
AR (1) | AR068919A1 (es) |
AT (1) | ATE522523T1 (es) |
AU (1) | AU2008313775B2 (es) |
CA (1) | CA2697982C (es) |
CL (1) | CL2008003067A1 (es) |
ES (1) | ES2371863T3 (es) |
IL (1) | IL205102A (es) |
JO (1) | JO2784B1 (es) |
MX (1) | MX2010004176A (es) |
PA (1) | PA8799901A1 (es) |
PE (1) | PE20091080A1 (es) |
RU (1) | RU2476433C2 (es) |
TW (1) | TW200934491A (es) |
WO (1) | WO2009050185A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20115241B (en) * | 2006-10-19 | 2011-06-10 | Takeda Pharmaceutical | Indole compound |
ES2424023T3 (es) * | 2007-10-18 | 2013-09-26 | Janssen Pharmaceutica N.V. | 1,2,4-triazoles trisustituidos |
AU2009226988B2 (en) * | 2008-03-19 | 2013-05-23 | Janssen Pharmaceutica Nv | Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators |
BRPI0912196A2 (pt) * | 2008-05-09 | 2015-10-06 | Janssen Pharmaceutica Nv | pirazóis trissubstituídos como moduladores do receptor de acetilcolina. |
CA2825519A1 (en) | 2011-02-03 | 2012-09-08 | Lupin Limited | Pyrrole derivatives used as modulators of alpha7 nachr |
CA2826792A1 (en) | 2011-02-23 | 2012-08-30 | Lupin Limited | Heteroaryl derivatives as alpha7 nachr modulators |
EP2678315B1 (en) | 2011-02-25 | 2015-12-16 | Janssen Pharmaceutica, N.V. | (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR |
EP2691368A1 (en) | 2011-03-31 | 2014-02-05 | Lupin Limited | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease |
US8946432B2 (en) | 2011-07-05 | 2015-02-03 | Lupin Limited | Biaryl derivatives as nAChR modulators |
US9388196B2 (en) | 2012-03-06 | 2016-07-12 | Lupin Limited | Thiazole derivatives as alpha 7 nAChR modulators |
WO2014072957A1 (en) | 2012-11-12 | 2014-05-15 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
EP2945941B1 (en) | 2013-01-16 | 2016-12-07 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
EP2970180A1 (en) | 2013-03-13 | 2016-01-20 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
TW201446243A (zh) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
US9504680B2 (en) | 2013-06-17 | 2016-11-29 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE795907A (fr) * | 1972-02-25 | 1973-06-18 | Luso Farmaco Inst | 2-amino-4-arylthiazoles 5-substitues et leur preparation |
EP0248523B1 (en) | 1986-05-07 | 1991-10-16 | FISONS plc | Pyrazoles |
JPS6339868A (ja) | 1986-08-04 | 1988-02-20 | Otsuka Pharmaceut Factory Inc | ジ低級アルキルフエノ−ル誘導体 |
US4761422A (en) | 1986-11-20 | 1988-08-02 | Lusofarmaco Istituto Lusofarmaco D'italia Spa | (2-amino-4-aryl-thiazole-5-yl)ethanols and their derivatives having diuretic activity and methods for preparing the same |
WO1996003392A1 (en) | 1994-07-27 | 1996-02-08 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
KR970705560A (ko) | 1995-08-02 | 1997-10-09 | 호아껭 우리아치 토렐로 | 항진균 활성을 갖는 신규한 카르복사미드(new carboxamides with antifungal activity) |
FR2754258B1 (fr) | 1996-10-08 | 1998-12-31 | Sanofi Sa | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
ATE236890T1 (de) | 1996-12-23 | 2003-04-15 | Bristol Myers Squibb Pharma Co | Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
CA2302417A1 (en) | 1997-10-27 | 1999-05-06 | Takeda Chemical Industries, Ltd. | Adenosine a3 receptor antagonists |
FR2792314B1 (fr) | 1999-04-15 | 2001-06-01 | Adir | Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
ATE257827T1 (de) | 1999-07-21 | 2004-01-15 | Hoffmann La Roche | Triazolderivate |
WO2001010865A1 (fr) | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | INHIBITEURS DE p38MAP KINASE |
FR2802530B1 (fr) | 1999-12-17 | 2002-02-22 | Sanofi Synthelabo | Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant |
WO2001064674A1 (en) | 2000-03-01 | 2001-09-07 | Janssen Pharmaceutica N.V. | 2,4-disubstituted thiazolyl derivatives |
US6586453B2 (en) | 2000-04-03 | 2003-07-01 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
US6515005B2 (en) | 2000-09-21 | 2003-02-04 | Bristol-Myers Squibb Company | Substituted azole derivatives as inhibitors of corticotropin releasing factor |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
CA2432870A1 (en) | 2000-12-22 | 2002-07-25 | Ronghui Lin | Substituted triazole diamine derivatives as kinase inhibitors |
HUP0401748A3 (en) | 2001-08-13 | 2011-03-28 | Janssen Pharmaceutica Nv | 2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them |
EP1441732A2 (en) * | 2001-11-08 | 2004-08-04 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivative and pharmaceutical use thereof |
CA2474322A1 (en) | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
CN1561340B (zh) * | 2002-01-28 | 2012-05-23 | 株式会社富士药品 | 1,2,4-三唑类化合物 |
US7300933B2 (en) * | 2002-05-07 | 2007-11-27 | Neurosearch A/S | Diazabicyclic biaryl derivatives |
WO2004013120A1 (en) * | 2002-07-29 | 2004-02-12 | F. Hoffmann-La Roche Ag | Novel benzodioxoles |
CL2003002353A1 (es) * | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
US20070191267A1 (en) | 2003-04-28 | 2007-08-16 | Ab Science | Use of tyrosine kinase inhibitors for treating cerebral ischemia |
CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
PT1635824E (pt) * | 2003-06-03 | 2009-11-24 | Novartis Ag | Inibidores de p-38 à base de heterociclos de 5 membros |
US20090018150A1 (en) | 2003-07-24 | 2009-01-15 | Asterand Uk Limited | 5-Ht2b Receptor Antagonists |
FR2862647B1 (fr) | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
GB0401336D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
CN1942450A (zh) * | 2004-02-11 | 2007-04-04 | 詹森药业有限公司 | 取代三唑化合物的制备方法 |
ZA200702645B (en) * | 2004-09-17 | 2008-08-27 | Vertex Pharma | Diaminotriazole compounds useful as protein kinase inhibitors |
DK1811998T3 (da) | 2004-10-21 | 2011-02-14 | Vertex Pharma | Triazoler anvendelige som inhibitorer af proteinkinaser |
WO2006064375A2 (en) | 2004-12-16 | 2006-06-22 | Ab Science | Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases |
MX2007008434A (es) * | 2005-01-19 | 2007-07-25 | Squibb Bristol Myers Co | Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos. |
CN101263130B (zh) * | 2005-09-13 | 2011-03-09 | 詹森药业有限公司 | 2-苯胺-4-芳基取代的噻唑衍生物 |
JO3019B1 (ar) | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
ES2424023T3 (es) * | 2007-10-18 | 2013-09-26 | Janssen Pharmaceutica N.V. | 1,2,4-triazoles trisustituidos |
AU2009226988B2 (en) * | 2008-03-19 | 2013-05-23 | Janssen Pharmaceutica Nv | Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators |
WO2009127678A1 (en) | 2008-04-17 | 2009-10-22 | Glaxo Group Limited | Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71 |
BRPI0912196A2 (pt) * | 2008-05-09 | 2015-10-06 | Janssen Pharmaceutica Nv | pirazóis trissubstituídos como moduladores do receptor de acetilcolina. |
KR101710197B1 (ko) * | 2009-09-17 | 2017-02-24 | 얀센 파마슈티카 엔.브이. | 치환된 n-페닐-1-(4-피리디닐)-1h-피라졸-3-아민 |
JO3078B1 (ar) * | 2009-11-27 | 2017-03-15 | Janssen Pharmaceutica Nv | مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة |
EP2678315B1 (en) | 2011-02-25 | 2015-12-16 | Janssen Pharmaceutica, N.V. | (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR |
-
2008
- 2008-09-15 JO JO2008412A patent/JO2784B1/en active
- 2008-10-15 EP EP08805280A patent/EP2205594B1/en active Active
- 2008-10-15 JP JP2010529360A patent/JP2011500624A/ja active Pending
- 2008-10-15 AU AU2008313775A patent/AU2008313775B2/en not_active Ceased
- 2008-10-15 CN CN2008801119538A patent/CN101827839B/zh not_active Expired - Fee Related
- 2008-10-15 ES ES08805280T patent/ES2371863T3/es active Active
- 2008-10-15 US US12/738,725 patent/US8404851B2/en active Active
- 2008-10-15 MX MX2010004176A patent/MX2010004176A/es active IP Right Grant
- 2008-10-15 AT AT08805280T patent/ATE522523T1/de not_active IP Right Cessation
- 2008-10-15 RU RU2010119458/04A patent/RU2476433C2/ru active
- 2008-10-15 WO PCT/EP2008/063844 patent/WO2009050185A1/en active Application Filing
- 2008-10-15 CA CA2697982A patent/CA2697982C/en active Active
- 2008-10-16 CL CL2008003067A patent/CL2008003067A1/es unknown
- 2008-10-17 PA PA20088799901A patent/PA8799901A1/es unknown
- 2008-10-17 PE PE2008001789A patent/PE20091080A1/es active IP Right Grant
- 2008-10-17 TW TW097139807A patent/TW200934491A/zh unknown
- 2008-10-17 AR ARP080104545A patent/AR068919A1/es not_active Application Discontinuation
-
2010
- 2010-04-15 IL IL205102A patent/IL205102A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
AR068919A1 (es) | 2009-12-16 |
CA2697982C (en) | 2015-09-22 |
ES2371863T3 (es) | 2012-01-10 |
RU2476433C2 (ru) | 2013-02-27 |
EP2205594A1 (en) | 2010-07-14 |
US8404851B2 (en) | 2013-03-26 |
CN101827839A (zh) | 2010-09-08 |
AU2008313775B2 (en) | 2012-12-13 |
JO2784B1 (en) | 2014-03-15 |
IL205102A (en) | 2015-04-30 |
PA8799901A1 (es) | 2009-05-15 |
CA2697982A1 (en) | 2009-04-23 |
CN101827839B (zh) | 2012-10-24 |
EP2205594B1 (en) | 2011-08-31 |
ATE522523T1 (de) | 2011-09-15 |
WO2009050185A1 (en) | 2009-04-23 |
TW200934491A (en) | 2009-08-16 |
AU2008313775A1 (en) | 2009-04-23 |
JP2011500624A (ja) | 2011-01-06 |
US20100240707A1 (en) | 2010-09-23 |
RU2010119458A (ru) | 2011-11-27 |
MX2010004176A (es) | 2010-05-03 |
PE20091080A1 (es) | 2009-08-03 |
IL205102A0 (en) | 2010-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008003067A1 (es) | Compuesto 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida, modulador de receptores nicotinicos alfa-7; proceso de preparacion; composicion farmaceutica y su proceso de preparacion; y su uso en el tratamiento de trastornos psicoticos, intelectuales, inflamatorios. | |
CL2008000670A1 (es) | Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras. | |
CL2007003774A1 (es) | Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis. | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
CL2007003192A1 (es) | Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario. | |
CL2006002831A1 (es) | Compuestos derivados de sulfonamida: proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por el receptor de glucocorticoides. | |
CL2011000735A1 (es) | N-[4-({4-[3-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)ureido]naftalen-1-il-oxi}metil)piridin-2-il]-2-metoxiacetamida; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de epoc, asma, dermatitis de contacto, artritis, entre otros. | |
CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
CL2007002669A1 (es) | Compuestos derivados de benzoxazol-2,7-disustituido y oxazol[5,4-c]-piridina; proceso de fabricacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por las cinasas jack2 y/o jack3 tal como cancer. | |
CL2007002610A1 (es) | Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras. | |
CL2009000628A1 (es) | Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros. | |
AR068369A1 (es) | Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina" | |
CL2008003822A1 (es) | Compuestos derivados de n1-(2-tiazolil)-1,2-dicarboxamida pirrolidina; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades mejoradas por la inhibicion de la fosfatidilinositol-3-cinasa, como el cancer. | |
CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
CL2007001530A1 (es) | Compuestos derivados de tiazol, inhibidores de fbpasa; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de diabetes mellitus tipo i, ii y iii, desequilibrio de glucosa en ayunas, desequilibrio en la tolerancia de la glucosa y complicaciones de la diabetes. | |
CL2007003265A1 (es) | Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras. | |
CL2008000089A1 (es) | Compuestos derivados de 2,4-pirimidinona condensada con un heterociclo, inhibidores de pde-4; composicion farmaceutica; combinacion farmaceutica; procedimiento de preparacion de los compuestos, utiles para tratar trastornos inmunes e inflamatorios. | |
CL2007003733A1 (es) | Compuestos derivados de indolin-2-ona, bencimidazol-2-ona y benzoxazol-2-ona, moduladores de serina palmitoiltransferasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 1 y 2, obesidad, aterosclerosis, hi | |
CL2007002689A1 (es) | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. | |
BRPI0816814A2 (pt) | composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação. | |
CL2007003472A1 (es) | Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie | |
CL2008003546A1 (es) | Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii. | |
CL2008000875A1 (es) | Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras. | |
CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. |